TScan Therapeutics, Inc.
TCRXNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $10.3M | $2.8M | $21.0M | $13.5M | $10.1M | $1.1M |
| Operating income | −$135.8M | −$134.8M | −$93.5M | −$66.6M | −$48.6M | −$26.2M |
| Net income | −$129.8M | −$127.5M | −$89.2M | −$66.2M | −$48.6M | −$26.1M |
| Total assets | $228.8M | $371.1M | $272.1M | $199.1M | $188.1M | $49.7M |
| Total liabilities | $105.7M | $130.1M | $121.3M | $99.7M | $27.3M | $32.5M |
| Equity | $123.1M | $241.0M | $150.9M | $99.4M | $160.8M | −$42.5M |
| EPS (diluted) | $-1.00 | $-1.14 | $-1.36 | $-2.75 | $-4.17 | — |
| Shares out. | 129.8M | 112.0M | 65.6M | 24.0M | 11.7M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1315.4%
- Net margin
- −1256.8%
- Return on equity
- −105.4%
- Return on assets
- −56.7%
- Return on capital (ROCE)
- −64.6%
- Liabilities / assets
- 46.2%
- Debt / equity
- 0.86×
- Book value / share
- $0.95
- Revenue growth (YoY)
- 266.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -5.99distress
- Accruals / assets
- 2.4%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Recruitingreadout ~2026-06A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
- Phase 1Active Not Recruitingreadout ~2026-12-30A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Biotechnology Value Fund L PPassive (13G)May 15, 2026
- Lynx1 Capital Management LpPassive (13G)Aug 14, 2025
- Adage Capital Management, L.P.Passive (13G)Aug 12, 2025
- Blackrock, Inc.Passive (13G)Jul 16, 2025
- Ecor1 Capital, LlcPassive (13G)May 15, 2025
- K2 Healthventures Equity Trust LlcPassive (13G)Feb 14, 2025
- Adage Capital Partners Gp, L.L.C.Passive (13G)Feb 12, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 876,559 | 1.0 | +0.7% |
| Apr 30, 2026 | 870,161 | 1.0 | -7.7% |
| Apr 15, 2026 | 942,877 | 1.0 | -50.0% |
| Mar 31, 2026 | 1.9M | 3.8 | -0.4% |
| Mar 13, 2026 | 1.9M | 2.7 | -1.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Amended charter or bylaws · Shareholder voteMay 22, 2026
- Results of operationsMay 6, 2026
- Director / officer changeApr 2, 2026
- Results of operationsMar 4, 2026
- Regulation FD disclosureJan 12, 2026
- Director / officer changeNov 26, 2025
- Results of operationsNov 12, 2025
- Costs from exit or disposal · Regulation FD disclosure · Other material eventNov 3, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.